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Objective: Assessing the effects of caffeine withdrawal on migraine.
Background: The effects of caffeine withdrawal on migraineurs are at large unknown.
Methods: This was a randomized, double-blind, crossover study (NCT03022838),
designed to enroll 80 adults with episodic migraine and a daily consumption of
300–800mg caffeine. Participants substituted their estimated dietary caffeine with either
placebo capsules or capsulated caffeine tablets for 5 weeks before switching the
comparators for 5 more weeks.
Results: The study was terminated due to low recruitment. Ten subjects with amean age
of 46.3 ± 9.9 years, BMI of 24.9 ± 3.7, and a mean blood pressure of 134/83 ± 17/12
mmHgwere enrolled. The average consumption of caffeine per day was 539± 196.3mg.
The average monthly headache days and migraine attack frequency at baseline was 11.5
± 4.9 and 5.2 ± 1.2, respectively. At baseline Pittsburgh Sleep Quality Index was 5.8 ±
2.5 and HIT-6 was 62.8 ± 3.9. There were no differences in these or in parameters from
actigraphy during the caffeine period compared with the placebo period. One subject
withdrew just after entering the study. In the remaining nine, withdrawal triggered severe
migraine attacks in seven, causing one more drop-out, and a typical caffeine withdrawal
syndrome in two. Caffeine continuation did not trigger migraines, but one attack occurred
in the wake of caffeine reintroduction.
Conclusions: The study failed to answer how caffeine withdrawal affects migraineurs
over time, but showed that abrupt withdrawal of caffeine is a potent trigger for
migraine attacks.
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INTRODUCTION
Active migraine affects more than 10% of the population, and may cause years of disability in many
(1). Caffeine is the most widely psychoactive substance used (2). The effects on migraine are not
fully understood, and the effects of withdrawal of caffeine on migraine has been little explored. In
healthy adults, cessation of daily doses of as little as 100mg of caffeine, the equivalent of one cup of
coffee, may cause a withdrawal syndrome consisting of headaches, lethargy, and other symptoms
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(3). Curiously, this syndrome mimics the prodromal phase of
migraine, and this seems to have been overlooked when the
symptoms of caffeine withdrawal have been investigated (4).
Studies explicitly documenting caffeine withdrawal as a trigger
for migraine seem to be lacking.
Caffeine is strongly incriminated as a major causes of
medication-overuse headache (5–7), and a strong positive
correlation between caffeine consumption and both episodic (8)
and chronic migraine (9) has been found in cross sectional
studies. Caffeine-overusemay cause chronic headache in children
(10), and the majority appears to be migraine related (11).
From the findings in a retrospective population-based study,
Scher et al. (12) concluded that dietary and medicinal caffeine
consumption is only a modest risk factor for developing chronic
daily headache, including chronic migraine. Furtehrmore, in a
Norwegian large-scale cross-sectional population-based study,
only a small association between high consumption of caffeine
(>540 mg/d) and infrequent migraine was found (13). Chronic
headache was actually associated with a low caffeine consumption
(mean of 125 mg/d). In a recent prospective cohort study of
adults with episodic migraine a non-linear association between
caffeinated beverage intake and the odds of migraine headacahe
occurrence on that day was found (14).
In this study we wanted to assess how sudden caffeine
withdrawal in subjects with established episodic migraine and a
regular moderate caffeine consumption would trigger migraine
attack or a caffeine withdrawal syndrome. The main objective,
however, was to study the “long-term” effects (headache days) on
migraine. Effects on sleep and quality of life were also assessed.
METHODS
Subjects for Inclusion
In accordance with guidelines for controlled trials of drugs
in migraine by the International Headache Society Clinical
Trial Subcommittee (15) adults, age 18–65, both women and
men suffering from migraine for at least 1 year and fulfilling
the diagnostic criteria of the International Headache Society
(IHS) (16), were in general eligible for this study. Otherwise
they had to be healthy, but having 3–6 attacks of migraine
per month, not currently taking other medications interacting
with caffeine, consuming caffeine ≥ 300mg ≤ 800mg every
day for at least 1 month, and motivated to go through with
caffeine withdrawal.
Women of fertile age had to use safe contraception,
meaning barrier methods (e.g., condoms or cervical cap),
hormonal methods (e.g., the pill), intrauterine devices and
sterilization to ensure not getting pregnant during the study
period. Conventional acute attack treatment was accepted,
but not sporadic use of other drugs like hypnotics and
anxiolytics. Subjects were obliged to substitute the caffeine
they normally consumed with the caffeine or placebo they
were provided with in the study. Even small doses of caffeine
can be sufficient to suppress caffeine withdrawal headache
(17), and an extra estimated average intake per day ≥25mg
in the study period was considered a breach qualifying for
exclusion. Other exclusion criteria included excessive use of
drugs for headache/suspicion of medication overuse headache
or chronic migraine, pregnancy and breast feeding, serious
co-morbidity or conditions contradicting the consumption of
caffeine, working night shift, and use of drugs with moderate
or major interactions with caffeine (e.g., tizanidine, lithium,
phenylpropanolamine, clozapine, theophylline, adenosine,
duloxetine, and ciprofloxacin). Several drugs are known to
interact with caffeine, but the majority only of minor importance.
All use of drugs were recorded and checked against interactions.
Recruitment
Subjects were recruited through ordinary ambulatory clinical
consultations and advertisements in the servicing area of
Nordland Hospital in Bodø and The University Hospital of
Tromsø. The study was also advertised through local radio.
Letters to local general practitioners were also sent out.
Enrollment and Study Procedure
Subjects who volunteered to participate received calendars
(http://www.bash.org.uk/about/headache-diary/formigraine/
attack/registrations), and in a 4 week run-in phase they
recorded their migraine attacks. After the run-in phase study
subjects came to the first visit for confirming diagnosis,
clinical examination, information, and for re-evaluation





Baseline 5.20 ± 1.22 Total sleepPlacebo,
min/night
436.00 ± 35.00
Placebo 4.89 ± 1.36 Total sleepCaffeine,
min/night
418.22 ± 37.17











Baseline 11.50 ± 4.88 AwakeningsCaffeine,
min/night
37.43 ± 9.35
Placebo 11.33 ± 2.45 Sleep efficacyPlacebo,% 86.09 ± 5.09
Caffeine 12.75 ± 8.15 Sleep efficacyCaffeine,% 85.16 ± 3.78
PSQI







Placebo 4.33 ± 1.50
Caffeine 5.38 ± 1.92
HIT-6 Blood pressure,
mmHg
Baseline 62.80 ± 3.91 Baseline 134/83 ± 17/12
Placebo 62.33 ± 3.84 Placebo 129/86 ± 16/13
Caffeine 62.13 ± 8.58 Caffeine 136/82 ± 21/13
HIT-6, Headache Impact Test; PSQI, Pittsburgh Sleep Quality Index; WASO, Wake after
sleep onset. All values are mean ± Std.
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of their eligibility. Pittsburgh Sleep Quality Index (PSQI)
and Headache Impact Test (HIT-6) scores (see below) were
obtained, and an estimate of the daily total caffeine intake (TCI)
was calculated (http://www.clockworkreserach.com/caffeine-
calculator/). Actigraphy motion biosensors (Actiwatch Spectrum
Plus, Phillips Respironics) were worn on the wrist on the
non-dominant arm and obtained data during days 3 through 7
and during days 38 through 44. If enrolled, they had to sign an
informed consent form. From the point of enrollment, subjects
were randomized, and then substituted their daily dietary
caffeine with either capsulated placebo- or capsulated caffeine
tablets (Recip R©, 100mg). The total dose (placebo or caffeine)
was divided in smaller doses trying to imitate the normal pattern
of dietary caffeine intake. After 5 weeks treatment was switched.
Patients were informed to avoid TCI ≥ 25 mg/d in the active
study period, and a risk of caffeine withdrawal symptoms within
2 days of withdrawal.
Caffeine and Placebo Tablets
Kragerø Tablettproduksjon AS was responsible for providing
caffeine tablets and producing placebo to the sponsor. The
former, Koffein Recip tablets 100mg, are approved by the
Swedish medical product agency, and was imported. The placebo
tablets were made identical to these. A small amount of the herb
gentiana lutea, not known to affect headaches, was added to the
placebo tablets to obtain a bitter taste similar to the caffeine
tablets. Tablets were capsulated to look identical.
Randomization and Blinding
A list of fixed allocation sequence for treatment was sent to
the drug and placebo provider which used a validated system
to generate a corresponding list with randomized numbers and
randomized assignment of the study subjects to treatment arms
in a 1:1 ratio to ensure blinding. After assignment to intervention
from the list, the knowledge of the treatment was concealed from
both researcher and participant.
Meassurmenst and Outcomes
The main outcome was the mean difference in headache days
between the placebo and the caffeine period. The withdrawal
weeks (1 and 6) were not included.
A baselinemigraine attack frequency (AFbaseline) andmigraine
days (MDbaseline) were calculated based on the calendar
registrations. Registration continues during the whole study
period. Patients also completed the Pittsburgh Sleep Quality
Index (PSQIbaseline) and the HIT-6 (HIT-6baseline) which later was
repeated in week 10.
Secondary outcomes included comparison of the same arms
(placebo vs. caffeine) in migraine attack frequency, PSQI scores,
actigraph parameters and HIT-6 scores. The share of patients
in the interventional arm that developed caffeine withdrawal or
migraine syndrome was determined on the clinical evaluations 2
days after intervention (day 2 and 37).
The PSQI can be used to assess subjective sleep during
the previous month (18), but is not a specific instrument for
TABLE 2 | Withdrawal symptoms in each study participant.
Subject and
diagnoses
TCI, mg Symptoms in the wake of
caffeine continuation
Symptoms in the wake of
caffeine discontinuation*




1. MA, MOA, TTH 300 NA Full-blown migraine + muscle
pain in her legs
Full-blown migraine NA
2. MOA 700 NA Slight headache and tiredness,
but in the wake of a migraine
attack that started prior to
intervention
“Feeling great” NA
3. MOA, TTH 300 None Full-blown migraine NA NA
4. MOA, TTH 500 NA Caffeine withdrawal syndrome;
tension type headache,
tiredness, and lethargy




5. MOA, TTH 800 NA Difficulties concentrating, dizzy,
nausea, throwing up→
Full-blown migraine
Palpitations and troubles with
falling asleep.
NA
6. MOA, TTH 800 Rotatory vertigo, nausea,
slight headache
NA NA Withdrew due to vertigo in
the wake of caffeine
continuation.
7. MOA, TTH 500 None Full-blown migraine NA NA
8. MA, MOA 400 NA Full-blown migraine with visual
aura
NA Withdrew from the study
due to migraine in the wake
of placebo
9. MA, MOA 800 None Nausea, sweating, lethargy→
Full-blown migraine
NA NA
10. MOA 400 NA Fatigue and full-blown migraine None NA
NA, Not applicable; None, no symptoms experienced by the patient; MA, Migraine with aura; MOA, Migraine without aura; TCI, estimated total caffeine intake; TTH, Tension type
headache; *symptoms within 24 h.
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diagnosing insomnia (19). Polysomnography is the gold standard
of sleep assessment, but is quite an extensive and resource
intensive method. In later years, new technology has made
actigraphy a reliable and easy way to measure sleep in a less
invasivemanner. An actigraph is a small wrist-watch-sized device
that monitors movement by using an accelerometer that tracks
motion and creates a graph. In addition, a button can be pushed
to mark events such as bedtime or wake time. Actigraphs are
widely used to study sleep-wake cycles and circadian rhythms.
Several studies have compared actigraphy to polysomnography in
the assessment of e.g., insomnia and other sleep disturbances, and
found it to be a valid and cost-effective alternative (20–22). Total
sleep, sleep latency, sleep efficacy, and the number of episodes
awake during the night were used to assess sleep objectively. HIT-
6 is a reliable and valid tool for discriminating headache impact
across episodic and chronic migraine (23, 24).
Assesment of Withdrawal Symptoms
Since withdrawal symptoms are considered greatest 20–48 h after
the most recent intake of caffeine (25), each patient was seen by a
headache specialist (KBA and KIM) on day 2 after intervention
(day 2 and 37). The symptoms presented by the study subject
were recorded and categorized in accordance with criteria, either
as migraine (16) or (26) caffeine withdrawal.
Statistical Analyses
The sample size was calculated based on the primary outcome
measure. Meaningful response, cost vs. benefit, to caffeine
withdrawal is hard to define. However, using recommended
measures for clinical trials of migraine (27), a meaningful
intervention is defined as a 50% reduction in headache days
in 50% of the participants. To calculate the sample sizes
needed to detect a difference between the two main objective
binomial probabilities (success proportion in arm P1 and
P2) with specified significance level and power, the following
hypotheses were used: H0: P1 = P2 vs. H1: P1 6= P2,
where P1 = caffeine withdrawal (placebo) intervention and P2
= caffeine continuation (caffeine). With significance level 95%
(α = 0.05), using a one sided test on an equal sample size
from two proportions, the proportion P1 = 0.5 and P2 =
0.15 are considered sufficiently different to warrant rejecting the
hypothesis of no difference. Then the required sample size for two
arms to achieve a 90% power (β = 0.1) could be determined by
m (sample size arm) = 34, then N = 68. With a drop-out rate of
15%, 80 patients would be needed.
A paired t-test (two-tailed) was used to assess changes between
placebo and caffeine. The Chi squared test for a 2 × 2 frequency
table was applied to compare number of subjects with caffeine
withdrawal syndrome with caffeine withdrawal migraine. The
threshold for statistical significance was p < 0.05. Calculations
were made by using IBM SPSS Statistics 26.
Ethics and Study Registration
The study was conducted in accordance with Good Clinical
Practice (28), and approved by the regional ethics committee
(2015/1729REK nord) as well as by the Norwegian Medicine
TABLE 3 | Frequencies of migraine in the wake of placebo (caffeine withdrawal)
and caffeine continuation or caffeine reintroduction.
Placebo Caffeine
Migraine* Yes 7 1 8
No 2 7 9
Total 9 8 17
*Comparing caffeine withdrawal (placebo) with caffeine (continuation or reintroduction) as
atrigger, the Chi square with the use of Yates’ correction gives a significant difference (X2Y
= 7.244, p < 0.05).
Agencies. It was registered at: https://www.clinicaltrials.gov/ct2/
show/NCT03022838?cond=caffeine+withdrawal&rank=1.
RESULTS
The study started February 2017, and was terminated due to
low recruitment on July 22, 2019. The exact number of subjects
screened to participate was unfortunately not recorded. Just
after being launched and talked about in local radio, 50 subjects
volunteered through e-mail. However, it became soon clear that
the majority of subjects volunteering from the community in
general did not fulfill the inclusion criteria, and that the majority
of subjects found eligible through ordinary clinical practice, were
not willing to stop consuming dietary caffeine for 10 weeks. Only
10 subjects were enrolled and randomized, one male and nine
females, with a mean age of 46.3 ± 9.9 years, an average BMI of
24.9 ± 3.7, and a mean blood pressure (BP) of 134/83 ± 17/12.
The average consumption of caffeine per day was 539± 196.3mg.
All subjects suffered from migraine without aura, three of them
also experienced some attacks with aura. Eight subjects suffered
in addition from tension type headache. Two patients withdrew
from the study, one due to withdrawal symptoms, and one due
to potential side effects of caffeine. Table 1 summarizes the final
outcomes. Overall, no significant differences were found in either
headache or sleep outcomes. Table 2 summarizes the evaluations
of symptoms 2 days after interventions (day 2 and 37), and the
latter results are also shown as frequencies in Table 3. Comparing
the proportion of subjects who experienced migraine in the wake
of placebo (caffeine withdrawal) vs. caffeine (continuation or re-
introduction), the Chi square with the use of Yates’ correction
gives: X2Y = 7.244, p < 0.05.
DISCUSSION
Due to recruitment problems, this study failed to be completed
as planned. This may reflect how higly valued caffeine is, but
may also suggest that patients perceive (consciously or not) a low
intake as an attack trigger. Lack of awarnes, both in society and
among physicians, may also add to the problem. In the frequently
cited paper of Kelman about triggers of migraine (29), caffeine
withdrawal is not mentioned, perhaps because of the pharing in
the questionnaire. In some reviews, however, it is considered as a
quite common trigger (30), but solid documentation for this has
been lacking.
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A regular use of caffeine equivalent to the amount consumed
by the participants in this study has been estimated to
occupy up to 50% of adenosine receptors in the brain (31).
Evidence supports that adenosine receptors are involved in
headache pathophysiology (32), including migraine (4). Abrupt
caffeine withdrawal may cause rebound headache, a widely
known phenomenon, an well-documented also in randomized
controlled studies (3), but whether it triggers migraine is
largely unknown. In an observational study of 32 migraineurs
before and during Ramadan fasting, the number of migraine
days increased in average from 3.7 ± 2.1 to 9.4 ± 4.3 (p
< 0.001). The negative effect was attributed to dehydration
and caffeine withdrawal, but this was not specifically assessed
(33). Couturier et al. (34) suggested that caffeine withdrawal
could be related to weekend migraine. In the present study
caffeine withdrawal triggered severe migraine attacks in seven
out of nine. Caffeine continuation did not trigger migraine
in any of the study subjects, but one attack occurred in
the wake of caffeine reintroduction. Unfortunately, due to
the study protocol, triggered attacks could not be treated
with caffeine.
In a recent study, showing that caffeine does not affect
the susceptibility to cortical spreading depolarization, the
phenomenon considered responsible for the migraine aura, the
investigators conclude that the adverse or beneficial effects of
caffeine on headache seem unrelated to CSD pathophysiology,
consistent with the non-migrainous clinical presentation of
caffeine-related headache (35). Our study strongly indicates that
abrupt caffeine withdrawal in patients with migraine actually
triggers migraine. This was also noted in the early description of
caffeine-withdrawal headache by Dreisbach (36); in migraineurs
typical migraine syndromes ensued. Coturier et al. (34) linked
weekend attacks of migraine to caffeine withdrawal, but did not
assess this specifically. All of the three migraineurs with aura in
our study got attacks triggered by caffeine withdrawal, but only
one attack was with aura.
The primary objective of this study was to determine how
caffeine withdrawal over 5 weeks would affect the migraine
burden. The long-term effect of caffeine withdrawal is little
studied. Hering-Hanit and Gadoth reported 36 children with
chronic headache, none with a prior history of migraine,
who consumed excessive amounts of caffeine in the form of
cola drinks (in average ∼190mg caffeine/d), and of whom 33
completely recovered after gradual withdrawal. Three children
continued to have infrequent migraine without aura after
withdrawal (10). In a double blinded, randomized, placebo-
controlled, 12 week crossover study of 45 healthy subjects who
habitually consumed 4–6 cups of coffee a day, withdrawal caused
headaches during the first or second day in 19 (42%) (37).
Subjects reporting headaches during caffeine vs. non-caffeine
weeks were similar (ratio 1.1). However, what is obvious, but not
commented by the authors, is that when the withdrawal weeks
(week 1 and 7) are removed the ratio increases to 7.7. Despite
small numbers, the result indicates that long-term elimination of
caffeine may be beneficial in reducing headache burden. Subjects
also reported improved sleep during the non-caffeine weeks.
Due to the low number of participants, the present study failed
to demonstrate any long-term consequences of detoxification.
However, both fewer days with headache and lower PSQI
during the placebo period when compared to the caffeine period
were observed.
As suggested by Spencer (38), caffeine withdrawal in
migraineurs may serve as a human model for studying migraine.
Why withdrawal could act as a trigger is unknown, but it
is probably a consequence of an up-regulation of adenosine
receptors during regular caffeine intake (4). Increased sensitivity
to adenosine after withdrawal may increase excitability in
networks involved in migraine pathophysiology, lowering the
threshold for attacks. Fried et al. (32) suggested that it is the
adenosine receptor A2A signaling that contribute to headache
via modulation of intracellular cyclic adenosine monophosphate
(cAMP) in neurons and glia to subsequently affect glutaminergic
synaptic signaling. Based on an in vivo rat model of migraine,
(39) suggested that A2A receptor antagonism may offer
a novel approach to antimigraine therapy. Imaging studies
using positron emission tomography (PET) A1AR- (31) and
A2AR-ligands are suitable for studying the cerebral effects of
caffeine (40), and may perhaps also be suitable for studying
the effects of caffeine withdrawal as a trigger for migraine
in vivo.
In conclusion, this study offers evidence on the acute trigger of
migraine attacks following caffeine in migraine patients. Larger
studies are needed to vaildate the finding.
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